lets make pharma prices affordable

They were told that if they “refuse to step up,” the government will deploy every tool in its “arsenal to protect American families from continued abusive drug pricing practices,” without stating what those measures could be.

The companies to receive letters were AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EMD Serono, Roche’s subsidiary Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi